Moreover, human B cell subsets and their plasticity in disease states are only starting to be understood.
In this Review, we describe B cell functions with a focus on the roles of B reg cells in kidney diseases. We also discuss the application and potential adverse effects of B cell-targeting therapies in autoimmune kidney diseases and renal transplantation.
B cell development B cells display considerable phenotypic and functional diversity, with various subsets possessing specialized effector roles. B cell development begins in the fetal liver and continues in the bone marrow, where multiple checkpoints ensure that B cells that are released into the periphery express functional B cell receptors (BCRs) and are not specific for self-antigens. The autoreactivity of a BCR is tested at the immature B cell stage and the early bone marrow emigrant B lymphocytes are also referred to as transitional B cells. These immature B cells express immunoglobulin M (IgM) and IgD on their surface and are often characterized by a CD24 hi CD38 hi phenotype and a lack of the memory B cell marker CD27 (ref. 7 ). Immature B cells complete their development in the periphery, maturing into antigen-naive CD24 int CD38 int CD27 − B cells ( fig. 1 ). In response to antigen-specific stimulation, B cells can differentiate into plasmablasts, plasma cells and memory B cells 8 .
Nephrotic syndrome
A triad of symptoms, namely oedema, proteinuria >3.5 g/day and hypoalbuminaemia, which result from glomerular podocyte damage. Patients often present with marked hypercholesterolaemia.
Minimal change disease
A common cause of nephrotic syndrome in children and adults, which is characterized by minimal histological abnormalities visible by light microscopy, but in which podocyte effacement can be observed by electron microscopy.
Effector and regulatory B cells in immune-mediated kidney disease
Plasma cells are long-lived, terminally differentiated, antibody-producing cells and plasmablasts are their short-lived proliferating counterparts. These two cell types, which lack expression of the pan-B cell marker CD20, are collectively referred to as antibody-secreting cells. Plasma cells home to the bone marrow, where they continuously produce antibody to provide immediate protection to the host upon re-infection. Memory B cells recirculate and can be rapidly induced to differentiate into antibody-producing plasmablasts through interaction with cognate T cells. This memory response is typically more robust than the primary B cell response to antigen and generates high affinity, class-switched immunoglobulins 9 . Vaccination strategies capitalize on long-lived memory B cell responses, and most successful vaccines rely on the mounting of an antibody response 10 . An enhanced understanding of B cell development and differentiation and of their phenotypic and functional heterogeneity might enable the therapeutic targeting of specific B cell populations. In addition, monitoring changes in B cell populations may provide novel biomarkers of disease and treatment responses.
Effector functions of B cells B cells are key orchestrators of humoral immunity and can also influence T cell activation and tolerance through antigen presentation and cytokine secretion ( fig. 2 ). Early work in animals that have congenital B cell deficiency yielded contradictory results, with some studies reporting that the absence of B cells affected T cell responses, whereas others found no effect on T cells [11] [12] [13] . Moreover, mice that have congenital B cell deficiency have a number of additional immune defects that might have a direct effect on T cells, confounding the analysis of the effects of B cell loss 14, 15 . Thus, the immunoglobulin-independent functions of B cells have been deduced largely from investigating changes in CD4 + T cell responses following the transient depletion of B cells. For example, T cell subsets and T cell activation status were unaffected by B cell depletion in naive mice 16 . However, B cell depletion led to reduced T cell proliferation in response to antigen as well as reduced memory responses to pathogens 16 .
The existence of an antibody-independent contribution of B cells to immune responses is supported by the findings of studies in animals in which B cells were unable to secrete antibody. For example, in the MRL/lpr model of lupus, B cells were able to contribute to disease pathogenesis in the absence of serum antibody 17 . Similarly, seronegative patients with rheumatoid arthritis (RA) benefit from B cell depletion therapy using the anti-CD20 monoclonal antibody rituximab, although to a lesser extent than do patients who have circulating autoantibodies (that is, anti-cyclic citrullinated peptide antibodies or rheumatoid factor) 18 . Below, we discuss the evidence for pro-inflammatory and pathogenic roles of antibodies, B cell-mediated antigen presentation and cytokine secretion, focusing on immune-mediated kidney diseases and renal transplantation.
Antibody production. Autoimmunity is often characterized by the presence of self-reactive antibodies, such as autoantibodies directed against nuclear antigens in systemic lupus erythematosus (SLE), neutrophil and monocyte antigens in AAV, glomerular basement membrane (GBM) constituents in anti-GBM disease and IgG antibodies to abnormally glycosylated IgA1 in IgA nephropathy [19] [20] [21] . Autoantibodies are often used as disease markers, to define disease types or to monitor disease activity, and their pathogenicity in humans is often inferred from animal models or in vitro studies. Infrequently, direct pathogenicity of autoantibodies in patients is implied following placental transfer from an affected mother to the fetus 22, 23 . In transplantation, alloantibodies to polymorphic antigens such as human leukocyte antigens (HLA) are associated with poor long-term outcomes of renal allografts [24] [25] [26] [27] . The role of alloantibodies in renal transplantation was initially recognized in the setting of hyperacute rejection owing to the presence of preformed blood group antibodies or HLA antibodies 28 . In the clinic, hyperacute rejection has now been largely eliminated as a result of ABO-matching of donors and recipients, and of rigorous screening of patient serum for anti-donor HLA antibodies before transplantation. Donor-specific IgG antibodies can, however, be formed de novo and contribute to transplant rejection. This finding implicates the germinal centre reaction in the production of these antibodies.
The class of an immunoglobulin determines its effector functions, including its ability to activate the complement system or to bind to immunoglobulin crystallizable fragment (Fc) receptors, and can thereby affect disease pathogenesis. For example, in kidney transplant recipients with donor-specific antibodies (DSAs), acute antibody-mediated rejection was associated with complement component C4d-fixing IgG3 DSAs, whereas patients who did not experience antibody-mediated rejection were found to have an enrichment of IgG1 DSAs that lacked the ability to bind to C1q 29 . The selection of different IgG subclasses during class-switch recombination is influenced by the nature of the antigen, T cell help and secondary signals, such as Toll-like receptor (TLR) ligation or cytokine receptor activation 30 .
Key points
• B cells can promote disease through the production of antibodies, the release of pro-inflammatory cytokines and the presentation of antigen to T cells, which leads to T cell activation and polarization • Regulatory B (B reg ) cell subsets can attenuate disease through the action of the immunomodulatory cytokine IL-10 and various other mechanisms • An imbalance in the numbers or function of pro-inflammatory and regulatory B cell subsets is found in various immune-mediated renal diseases and in renal transplant cohorts • Quantitative and qualitative assessment of B cell subsets may lead to the identification of biomarkers that could predict disease outcomes or relapse and instruct therapeutic strategies • B cell depletion has been successfully used for the treatment of various autoimmune diseases that affect the kidneys; the utility of B cell depletion therapy in kidney transplantation remains uncertain • As the available agents that are used for total B cell depletion remove B reg cells as well as pro-inflammatory B cells, a need exists for more targeted approaches using novel agents or combination therapies
Membranous glomerulonephritis
A glomerular disease that is characterized by subepithelial immune complexes, which cause nephrotic syndrome and is frequently associated with the presence of autoantibodies to phospholipase A2 receptor or thrombospondin type 1 domain-containing protein 7A.
Induction therapy
The initial immunosuppressive therapy used at the time of transplantation or the initial therapy used to treat autoimmune diseases.
Germinal centre reaction
The process through which high-affinity, class-switched plasma cells and memory B cells are generated.
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As mentioned previously, terminally differentiated plasma cells and plasmablasts do not express CD20, which is the antigen target of several monoclonal antibodies that are used for B cell depletion therapy. Interestingly, treatment with rituximab is associated with a clinically significant reduction in autoantibody levels in patients with RA and AAV 3, 31 , despite the inability of this antibody to directly target antibody-secreting cells. This effect is thought to result from the depletion of precursor cells that maintain the population of shortlived, newly differentiating plasmablasts, which are an important source of autoantibodies 32 . Antigen presentation. B cells are able to function as antigen-presenting cells (APCs) owing to their endocytic capacity, antigen processing ability and close spatial proximity to T cells within lymphoid organs 33 . The binding of a specific antigen to an immunoglobulin receptor on the surface of a B cell leads to the capture, endocytosis and trafficking of that antigen to MHC class II-rich compartments. In contrast to the nonspecific antigen loading that occurs in myeloid APCs, this B cell mechanism favours the presentation of antigens that are either endocytosed after direct binding to the BCR or are associated with these endocytosed antigens. B cells may be particularly important for the presentation of low abundance antigens, such as autoantigens. Consequently, B cell depletion can reduce effective antigen presentation and lead to attenuation of T cell activation and effector function. This attenuation underlies some of the effectiveness of B cell depletion therapy in various clinical settings 34 . In the context of chronic cardiac graft rejection, studies in mouse models have demonstrated that B cells can support T cells in the alloimmune response and contribute to pathogenesis in an antibody-independent manner 35, 36 . Similarly, the ability of B cells to promote T cell activation through alloantigen presentation is observed in kidney transplant recipients who have antibody-mediated rejection 37 . In lupus-prone mice, B cells have been shown to act as APCs to elicit autoreactive T cell responses 38 . Of note, B cells can also act as APCs to tolerize T cells, for example in conditions of non-BCR-mediated antigen uptake 33 .
Cytokine production. B cells are able to release an array of pro-inflammatory and anti-inflammatory cytokines that can polarize T cell responses. Most of our mechanistic understanding of the role of B cell cytokine production in immune responses comes from animal studies 39 . Initial studies in mice showed that naive B cells could be polarized in vitro in the presence of T helper 1 (T H 1) cells and T H 2 cells to produce distinct effector cytokines 40 . These polarized cells were termed B effector 1 (Be1) cells and Be2 cells and were primed by IFNγ Be1 cells were originally thought to contribute to autoimmunity, whereas Be2 cells were thought to have a role in allergic responses. However, human counterparts of these polarized, cytokine-secreting B cell subsets have not been identified. Nevertheless, accumulating evidence from studies in humans and mice implicates the production of pro-inflammatory cytokines by B cells in disease pathology. In the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis (MS), B cell depletion only reduced disease severity in those animals whose B cells could produce IL-6 (ref.
42
). Similarly, in patients with MS who responded to rituximab, newly reconstituted B cells produced less IL-6 in response to in vitro stimulation via the BCR, CD40 and TLR9 than did the B cells that were present before rituximab therapy 42 . Patients with MS also have increased frequencies of pro-inflammatory granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing memory B cells, which co-express IL-6 and TNF 43 . The number of GM-CSF + B cells in these patients returned to baseline levels upon B cell repopulation following B cell depletion therapy, and this change was associated with a reduction in the myeloid pro-inflammatory response 43 . Whether IL-6 production by B cells is broadly relevant to pathology in autoimmune conditions has been called into question, as IL-6 production by B cells in response to TLR9 ligands is reduced in patients with SLE compared with healthy individuals 44 . Other proinflammatory cytokines that have been associated with immune-mediated pathologies that affect the kidneys, including glomerulonephritis 45, 46 , can be produced by B cells, particularly following infections, and include TNF and IFNγ.
B cells can be found within structures with features of tertiary lymphoid tissue in renal allografts 47 , in which their presence is associated with poor outcomes 48, 49 , and in the renal interstitium in some patients with tubulointerstitial nephritis 50 , AAV and SLE, where their numbers decrease with disease remission 51 . Whether B cells found within the kidneys secrete pro-inflammatory cytokines that contribute to immune pathology remains to be determined. 
Type 2 response
An immune response in which mainly T helper 2 (T H 2) cells produce cytokines, such as iL-4.
Tertiary lymphoid tissue
Organized lymphoid structures that develop in non-lymphoid tissues.
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Regulatory B cells
The term 'B reg cell' is used to refer to B cells with a number of different phenotypes that, through an expanding range of mechanisms, suppress pathogenic T cell responses and thus support immune tolerance. B reg cells have been described in mice and in humans 52 and are most commonly defined as B cells that produce IL-10 and limit inflammation. To date, no unique B reg cell marker has been discovered, and transcription factors that specifically drive the development of these cells have remained elusive. 57 and plasmablasts 58 . Importantly, whether B reg cells that derive from different B cell developmental or activation stages are indeed ontogenically distinct and whether these cells are equally suppressive is unknown. Even within the phenotypically defined CD24 hi CD38 hi immature B cell subset, in which B reg cells are enriched, functional differences exist, evidenced by the varying proportions of pro-inflammatory and anti-inflammatory cytokines that can be produced by these cells. These differences might have important consequences for host immune reactivity.
Development
Although most of the research on factors that drive B reg cell development has been carried out in mice, the signals that induce the differentiation of these cells in humans are also being uncovered. The available data suggest that, unlike natural regulatory T (T reg ) cells, which constitute a separate lineage of T cells of thymic origin, multiple B reg cell subsets can arise in the periphery in response to various cues, including binding to BCRs, CD40 and pattern-recognition receptors (in particular, TLRs), as well as in response to proinflammatory cytokines, all of which are elements of a successful immune response 59 . In mice, B reg cell development, which leads to the suppression of T H 17 cell responses, is dependent on the presence of proinflammatory cytokines, such as myeloid-derived IL-1 and IL-6 (ref. 54 ) as well as IL-21, which is produced by T cells 55 . These cytokines also drive the polarization and proliferation of T H 17 cells 60 . This mechanism suggests that B reg cells may arise during an immune response to promote immune homeostasis. Furthermore, in healthy individuals, low levels of IFNα can drive B reg cell differentiation, whereas high levels of this pro-inflammatory cytokine lead to the differentiation of plasmablasts that no longer produce IL-10 (ref. 53 ). Moderate levels of inflammation therefore seem to promote the induction and maintenance of B reg cells, which contributes to the restoration of homeostasis, whereas conditions of persistently high inflammation seem to inhibit the induction of B reg cells.
Of note, a requirement for BCR engagement in B reg cell development has been demonstrated using mice that have limited BCR specificity or that lack crucial molecules involved in BCR signalling 61 . In mouse models of MS (EAE), RA (collagen-induced arthritis (CIA)) and inflammatory bowel disease (IBD), CD40 has also been shown to be important in the generation and function of B reg cells 59, 62, 63 . CD40 stimulation increases IL-10 production by murine B cells 59, 62 , and mice with a B cellrestricted CD40 deficiency are unable to recover from EAE owing to a defect in IL-10 production. Similarly, in CIA 62 and in the MRL/lpr model of lupus 64 , adoptive transfer of CD40-stimulated B cells suppressed disease, whereas adoptive transfer of unstimulated B cells had no effect on disease severity. CD40 has also been demonstrated to potentiate the in vitro suppressive capacity of human immature CD24 hi CD38
hi B cells, and this effect was mediated, at least in part, by IL-10 (ref.
56
).
Finally, TLR agonists are potent inducers of IL-10 production by mouse and human B cells in vitro 65 . Mice with a global deficiency in the TLR adaptor protein MYD88 are resistant to EAE, whereas those with a B cell-specific deletion of both Tlr2 and Tlr4 or of Myd88 develop a chronic inflammatory disease that is associated with their inability to control T celldriven inflammation 66 . In addition, lipopolysaccharide (LPS)-induced B reg cells have been shown to suppress pancreatic inflammation in non-obese diabetic (NOD) mice 67 . Taken together, these data suggest that antigenspecific recognition, CD40 ligation and the activation of pattern-recognition receptors, in addition to acute inflammation, are important inducers of B reg cells and their IL-10 production.
Suppressive functions. The ability of B cells to suppress T cell responses was first recognized in the 1970s in studies investigating inflammatory responses in animal models of delayed-type hypersensitivity, in which the absence of B cells led to exacerbation of T cellmediated immune reactions. However, three reports published in the early 2000s, which showed that B cells could suppress immune responses in mouse models of autoimmunity, namely IBD 63 , EAE 59 and CIA 62 , challenged the paradigm that B cells could only positively contribute to autoimmune pathology. These studies showed that B cells could regulate disease manifestations and modulate inflammation, and that these effects were dependent on the production of IL-10. Subsequently, IL-10-producing B cells were shown to ameliorate disease in mouse models of arthritis by the suppression of T H 1 and T H 17 cell responses 68, 69 . These studies also found that B reg cells promote the proliferation of T reg cells and enhance their expression of the transcription factor FOXP3, a finding that is consistent with previous observations of reduced T reg cell numbers in B cell-deficient mice 70, 71 . Studies in mice suggest that plasmablasts produce considerable amounts of the regulatory cytokine IL-10 (ref. 58 ). Plasmablasts that produce another immunomodulatory cytokine, IL-35, have also been identified in mice and contribute to the suppression of inflammation, but these cells did not co-produce IL-10 (ref.
72
Interestingly, IL-35 has been shown to promote IL-10 production by human B cells through a positive NAtuRe Reviews | NEPhRology feedback loop, thereby contributing to the amplification of this suppressive pathway 73 . Human IL-10-producing B cells have been identified not only in the context of autoimmunity but also in infection and cancer. These cells can be beneficial in autoimmunity, as they suppress inflammatory responses through the inhibition of T cells and myeloid cells, and deficiencies in B reg cell number and suppressive function have been reported in various autoimmune conditions, including SLE 56, 74 , RA 75 , MS 76 and psoriasis 77 . However, in the context of infection or cancer, B reg cells have been shown to contribute to pathology, as they hinder protective immunity against viral pathogens and neoplasms 78 .
The immature B reg cell subset (CD24 hi CD38 hi ) can regulate T cell activation (as is evident from a reduction in the production of IFNγ and TNF by T cells) in an IL-10-dependent manner 56 . Importantly, these B reg cells are functionally impaired in patients with SLE and other autoimmune conditions 56 . In patients with active RA, not only were there fewer CD24 hi CD38 hi B reg cells, but these cells were also less able to inhibit T H 17 cell polarization and promote T reg cell induction than those from healthy individuals and patients with inactive RA 75 . Together, these results suggest that autoimmunity may be driven in part by an inability of B reg cells to inhibit an autoreactive immune response.
A second population of IL-10-producing B reg cells, termed B10 cells, was initially identified as a functionally distinct subset in mice but has now also been detected in human peripheral blood 57 . In humans, these cells are mostly found within the memory B cell population (CD24 + CD27 + ), and they suppress the production of pro-inflammatory cytokines by monocytes in an IL-10-dependent manner in vitro 57 . Patients with common variable immunodeficiency, who may develop autoimmune diseases, have reduced T reg cell function and reduced numbers of IL-10-producing B cells; however, the T reg cell defect did not correlate directly with the reduced abundance of B reg cells 79 . Human B reg cells have also been reported to modulate T cell responses by mechanisms other than IL-10 production, for example by production of the immunomodulatory cytokine transforming growth factor-β (TGFβ), by production of indoleamine 2,3-dioxygenase (IDO), which alters T cell activation through the breakdown of the essential amino acid tryptophan, by expression of programmed cell death 1 ligand 1 (PDL1), which engages the inhibitory receptor programmed cell death 1 (PD1) on T cells [80] [81] [82] , and by the combined secretion of IL-10 and IgG4 (ref.
83 ) ( ). Of note, the cell surface marker CD1d, which is highly expressed on many of the identified B reg cell subpopulations in mice and humans, has a role in the presentation of lipids to invariant natural killer T cells (iNKT cells) 74, 85 . Although iNKT cells have dual roles in immunity, they are increasingly associated with immune regulation in autoimmune disease 86 . CD1d expression by B reg cells contributes to the regulation of inflammation in mice independently of IL-10 (ref.
87
In summary, human B reg cells can be found within vari ous B cell subsets and have the ability to regulate other immune cells within complex inflammatory circuits (TABLe 1) .
B cells in kidney disease B reg cells have now been studied in various diseases that affect the kidneys, including SLE, AAV and other connective tissues diseases, as well as in the context of renal transplantation. No two diseases seem to have identical B reg cell abnormalities, which can be a reduction in their abundance, their function or both. B reg cells have also been proposed as potential biomarkers of disease activity, which might be used to predict immune quiescence or future relapses (TABLe 2) .
Many diseases that lead to kidney dysfunction (such as anti-GBM disease, SLE and AAV) are defined by, or are associated with, the presence of autoantibodies. Furthermore, some kidney diseases that do not have clear autoantibody involvement, such as minimal change disease or focal segmental glomerulosclerosis, seem to respond to immunomodulatory therapy, suggesting that immune dysregulation contributes to their pathogenesis 88 .
As discussed above, B cells promote autoimmunity by producing pathogenic autoantibodies and proinflammatory cytokines and by activating self-reactive T cells through the presentation of self-antigens. Consequently, in autoimmune conditions, treatment is often directed at the immediate removal of antibodies (using plasmapheresis) or interference with their action (using intravenous immunoglobulins) as well as longterm suppression of B cell and T cell reactivity to prevent further proliferation and activation of self-reactive leukocytes. However, a more nuanced understanding of immune regulatory circuits has highlighted the effect that these therapies have on T reg cells and B reg cells, including potential short-term and long-term effects on disease pathogenesis.
Similarly, although alloreactive B cells are considered harmful in renal transplantation, settings exist in which in vitro B cell depletion results in increased alloreactivity, suggesting a potential regulatory role 37 . Importantly, end-stage renal disease is associated with changes in B cell immunity, as is evident from the finding that patients fail to mount robust responses to vaccinations 89 . Reports also exist of skewed B cell subpopulations in patients on dialysis, such as reduced levels of CD24 + CD38
− memory B cells and elevated levels of CD24 hi CD38
hi immature B cells compared with predialysis patients and healthy individuals 89 . Moreover, serum levels of IL-10 and IL-4 were higher in patients on dialysis than in predialysis patients 89 . These changes mean that analyses of cell subsets among patients with immune-mediated kidney disease should ideally take renal function into account and use appropriately matched case controls, which are often lacking. Another study documented an augmented population of IL-21-dependent granzyme-B-expressing B cells in tolerant patients compared with those with stable graft function on immunosuppressants 93 . These B cells suppressed CD4 + T cell activation by inducing apoptosis and inhibiting proliferation. This regulation was mediated through a direct T cell contact-dependent action of granzyme B and not by IL-10 or TGFβ. However, a 2016 analysis of validation cohorts of tolerant renal transplant recipients suggested that many of the earlier reported differences were confounded by the fact that some immunosuppressive medications that were used in the non-tolerant cohort have direct effects on B cell subsets, including modulation of gene expression 94 . For example, both glucocorticoids and azathioprine can substantially reduce the numbers of immature B cells, whereas calcineurin inhibitors do not have this effect (TABLe 3) . Nevertheless, when immunosuppressionindependent gene sets were analysed, a panel of nine genes, including BCL2A1, EEF1A1 and IGLC1, which are also expressed by B cells, was found to be highly predictive of the tolerant state 94 . Importantly, in a cohort of operationally tolerant liver transplant recipients, a different set of transcripts -those expressed by CD56 + lymphocytes (NK cells and T cells) -was significantly over-represented 95 , which may reflect differences in tolerogenic pathways in the liver and kidneys.
In addition to operationally tolerant patients, B cell populations and graft outcomes have been investigated in cohorts of transplant recipients on continuous immunosuppression. Higher numbers of CD24 hi CD38 hi IL-10-producing B reg cells have been found in patients with longer duration of graft survival 96 and in those with fewer rejection episodes 97, 98 , suggesting that these cells might be of use either as a biomarker for improved graft outcomes or as a therapeutic intervention. Prospective studies have reported increased numbers of B cells that express IL-10 and granzyme B in patients with stable grafts over the first year of transplantation 99 . Interestingly, CD24 hi CD38 hi immature B cells with the highest IL-10:TNF ratio were enriched in patients with stable graft function, whereas in patients with chronic rejection, immature B cells had equivalent levels of IL-10 but higher levels of TNF 100 . The lower IL-10:TNF ratio correlated with poorer 3-year graft outcome, and the B cells from these patients were shown to be functionally less suppressive of T H 1 responses than those from patients with a higher IL-10:TNF ratio 100 . Further validation of these cells as biomarkers and the potential for their therapeutic manipulation is currently being investigated. AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; B reg cell, regulatory B cell; IDO, indoleamine 2,3-dioxygenase; IFNγ, interferon-γ; IgG4, immunoglobulin G4; iNKT cell, invariant natural killer T cell; PDL1, programmed cell death 1 ligand 1; SLE, systemic lupus erythematosus; T H 1 cell, T helper 1 cell; TNF, tumour necrosis factor ; T reg cell, regulatory T cell.
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The effect of immunosuppressive agents on B reg cell populations has also been investigated in other transplant cohorts, with some contradictory findings (TABLe 3) . For example, different agents used as induction therapy result in different proportions of B reg cells. Following repopulation, induction with alemtuzumab (a depleting monoclonal antibody directed against CD52, which is present on many leukocyte populations, including B cells) augmented naive, immature and CD5
+
CD1d
hi B cell numbers to a greater extent than did basiliximab (an anti-CD25 mAb and IL-2 receptor antagonist), and the alemtuzumab-treated patients had improved graft outcomes and lower levels of DSAs 101 . In ABO-incompatible renal transplant recipients, treatment with rituximab resulted in a predominantly naive B cell phenotype (with an increased proportion of IL-10-producing B reg cells) upon B cell repopulation 1 year following transplantation 99 . Increased rates of acute transplant rejection have also been reported following rituximab induction therapy 102 , possibly as a result of depletion of B reg cells, which express CD20; however, this is not a universal finding in rituximab studies 103, 104 . Results from ongoing trials of rituximab as an induction therapy are awaited. For maintenance therapy, patients treated with sirolimus or calcineurin inhibitors had reduced numbers of CD24 hi CD38
hi IL-10-secreting B reg cells compared with healthy controls 96, 98 . These findings suggest that certain immunosuppressive agents may have greater effects on the B reg cell population than others.
Patient stratification based on B reg cell populations needs to be validated prospectively, and perhaps optimized for clinical ease of use, as current methods for the detection of IL-10 are complex. However, such stratification could potentially provide a rationale for augmenting or reducing immunotherapy at an early stage after transplantation to improve graft outcomes and reduce the burden of immunosuppression in those patients who are most likely to benefit. In addition, strategies that augment B reg cell numbers or function in renal transplant recipients may be beneficial in maintaining the long-term function of grafts, reducing the generation of alloantibodies and perhaps facilitating the restoration of tolerance.
Systemic vasculitis.
Small vessel pauci-immune AAV is frequently characterized by the presence of ANCAs, which are autoantibodies directed against neutrophil and monocyte proteins. This disease often results in renal involvement, which progresses to end-stage renal disease in some patients. B cell involvement is common in proteinase 3 (PR3)-ANCA-associated and myeloperoxidase (MPO)-ANCA-associated disease and is confirmed by the clinical success of anti-CD20 antibody-mediated B cell depletion in both induction and maintenance therapy [1] [2] [3] . Limited reports of a benefit of anti-CD20 mAbs in ANCA-negative systemic vasculitis also exist, suggesting a mechanism of action beyond autoantibody reduction 105 . Importantly, in AAV, B cells are found at the sites of inflammation, both within inflamed kidneys 106 and in inflammatory granulomatous lesions 107 . The role of B reg cells in mediating AAV remission, their potential use as biomarkers of stable disease and more broadly the use of B cell subset distribution as a possible predictor of future relapses, have all been studied in various single-centre cohorts and clinical trials. An important caveat in interpreting the results of these studies is that different groups have used distinct cell surface markers for the characterization of B reg cells; only some studies focused on IL-10 production and few [109] [110] [111] and to patients in remission 110, 111 . Conversely, an increase in the frequency of IL-10-producing B reg cells has been reported following B cell repopulation in patients successfully treated with rituximab, suggesting that CD20 depletion is effective in restoring the balance between effector B cells and B reg cells. In these studies, the cytokine profile of repopulating B cells has been proposed as a predictor of disease relapse 110, 112 . Other studies have used the co-expression of CD19 and CD5 as surrogate B reg cell markers. This CD5 + B cell population has been shown to produce IL-10 (ref. 113 ). CD19 + CD5 + B cell numbers decrease during acute AAV but increase to normal levels during disease remission 114 . Following rituximab therapy, patients with normalized CD19 + CD5 + B cell frequencies in repopulating B cells experienced longer time to relapse compared with patients whose CD19 + CD5 + B cells did not repopulate to the same extent 115 . However, the predictive utility of measuring CD19 + CD5 + B cell numbers for assessment of disease relapse following either rituximab or conventional cyclophosphamide-based therapy was not validated in an analysis of data from the RAVE trial 3 . In fact, the number of CD5 + B cells was found to be highly variable from the time of acute disease to remission, and no association with subsequent relapses was observed 116 . Systemic lupus erythematosus. SLE was one of the first human diseases in which autoimmunity was found to be associated with abnormalities in B cell subsets, including B reg cell dysfunction 56 . Patients with SLE present with polyclonal B cell activation, elevated immunoglobulin levels and various autoantibodies 117 . Moreover, genetic studies of patients with SLE have identified polymorphisms in genes that influence B cell development, activation and signalling, leading to the development of autoreactive B cells, and animal models have further confirmed a key role for B cells in disease pathogenesis 118 . Paradoxically, clinical trials of B cell depletion agents have not demonstrated a clinical benefit in SLE [119] [120] [121] . Nevertheless, the targeting of B cell survival through the inhibition of B cell-activating factor (BAFF; also known as TNFSF13B) has shown success in the treatment of less severe disease manifestations, such as skin and joint manifestations in some trials 122 . The failure of rituximab and certain BAFF inhibitors in SLE trials is in contrast to clinical experience and treatment guidelines 123 . Numerous reasons for these failed trials have been proposed, including the liberal additional use of glucocorticoids to treat patients (potentially masking a beneficial effect of rituximab) and the inability of rituximab to successfully deplete memory B cells in tissues 123 . Clinical data have shown that the abundance of IL-10 + B cells inversely correlates with lupus activity 56 . Although the numbers of CD24 hi CD38 hi B cells are comparable between healthy controls and patients with SLE, the proportion of these cells that produce IL-10 is lower in patients, particularly in those with lupus nephritis, than in healthy individuals 124 . This defect in IL-10 production leads to a reduced ability of CD24 hi CD38
hi B cells from patients with SLE to inhibit T H 1 cell responses compared to those of healthy individuals 56 . In addition, the frequency of IL-10-producing cells within the naive B cell pool (that is, CD27 − CD38 int IgD + B cells) is reduced in patients with SLE, and these cells express higher levels of co-stimulatory molecules than those from healthy individuals, leading to enhanced T cell activation 125 . Although IL-21 usually drives B reg cell differentiation, in patients with SLE it promotes the expansion of a population of CD11c + T-bet + memory B cells that can differentiate into short-lived plasma cells 126 . The frequency of this memory B cell population correlated with disease activity.
Finally, patients with SLE can have defects in iNKT cell numbers and function 74, [127] [128] [129] , which may be due to abnormalities in B cells that are capable of presenting lipid antigens to iNKT cells. In particular, CD1d endocytic recycling is aberrant in B cells from patients with SLE, which results in reduced CD1d expression on the surface of B cells 74 . CD1d expression is restored in newly repopulating immature B cells in patients who respond to rituximab therapy and, interestingly, this restoration of CD1d expression correlates with the recovery of iNKT cell numbers and function. The association of clinical improvement with the restoration of B reg cell function could potentially be a useful marker of immunosuppression adequacy (TABLe 2) .
Other complex self-regulatory circuits that operate in healthy individuals are compromised in patients with SLE. For example, in healthy individuals, a negative feedback loop exists in which IFNα that is secreted by plasmacytoid dendritic cells (pDCs) drives plasmablast differentiation 130, 131 and induces the production of IL-10 by B reg cells, most of which belong to the CD24 hi CD38 hi immature B cell subset 53 . In turn, these B reg cells inhibit IFNα production by pDCs in an IL-10-dependent manner 53 . In patients with SLE, pDCs are hyperactivated and promote the differentiation of plasmablasts but not the induction of CD24 hi CD38
hi B reg cells 53 . This effect is driven, at least in part, by alterations in signal transducer and activator of transcription 1 (STAT1) and STAT3 signalling in immature B cells 53 . Although individual B cells can secrete TNF and IL-6, as well as IL-10, selective skewing of this balance may be beneficial and has been achieved in vitro using epratuzumab 132 . This antibody binds to CD22 and inhibits BCR-mediated activation in B cells from healthy individuals and from patients with SLE. This inhibition leads to reduced B cell proliferation and pro-inflammatory cytokine production, skewing the cytokine balance towards IL-10 production 132 . In patients with SLE, delayed reconstitution of peripheral memory B cells and greater repopulation of immature B cells following rituximab therapy are associated with prolonged disease remission 133 . This ratio of immature B cells to memory B cells may provide a useful biomarker to identify whether rituximab redosing is required to prevent subsequent disease flares (TABLe 2) .
Other immune complex-mediated disorders. B cell depletion therapy has been shown to be effective in various other immune complex-mediated renal disorders, including cryoglobulinaemia 4 and IgG4-related disease (IgG4-RD) 134 . Anecdotal reports of a clinical benefit of this therapy in fibrillary nephropathy 135 , IgA nephropathy and IgA vasculitis (formerly known as Henoch-Schonlein purpura) 136 also exist. In comparison to healthy individuals, patients with hepatitis C virus (HCV)-associated cryoglobulinaemia present with various immune perturbations, including reductions in the numbers of both naive and memory B cells as well as T reg cells, elevated numbers of T follicular helper (T FH ) and T H 17 cells and increased serum BAFF levels 137 . However, following rituximab therapy, B cell, T cell and monocyte-related genes, including TWEAK receptor, CCR2 and interferon-stimulated genes, are downregulated 137 . BAFF levels also increase following rituximab therapy, with a greater increase in those who subsequently relapse than in those who do not relapse 137 . In HCV-associated cryoglobulinaemia, a reduction in viral load ameliorates immune dysregulation, and patients who are treated with direct antiviral therapy alone (without rituximab) have an increase in PD1-expressing B cells and T reg cells, as well as a reduction in T FH cells, T H 17 cells and CD21 low memory B cells 138 .
In patients with IgG4-RD, investigation of B cell subsets identified a reduction in the frequency of CD24 hi CD38
hi immature B cells and lower BAFF receptor expression, whereas memory B cell and plasmablast numbers were increased compared with healthy controls 139 .
No functional studies of B cells were undertaken but, interestingly, serum IL-10 levels were higher in patients with IgG4-RD than in healthy individuals 139, 140 . This finding may be explained by the observation that IgG4 production is enriched in a subset of IL-10-producing B reg cells that express CD71 and CD25 (that is, BR1 cells), suggesting that, in this setting, B reg cell subsets contribute to disease through antibody production 83 . B cell depletion with rituximab has been reported to be of benefit in IgG4-RD and results in a significant reduction in the levels of CD19 ). However, changes in the levels of other B cell subsets were not examined. The number of plasmablasts returns to baseline levels at the time of relapse, suggesting that they may be a biomarker of disease activity and have a role in disease pathogenesis However, an open-label study demonstrated no benefit of rituximab added to standard care in terms of renal function or proteinuria in these patients, despite confirmation that B cells were effectively depleted, and this therapy had no effect on the levels of pathogenic antibodies against galactosedeficient IgA1 (ref. 142 ). By contrast, in a case series of patients with IgA vasculitis, rituximab therapy enabled minimization of steroid dose and led to an improvement www.nature.com/nrneph in the Birmingham Vasculitis Activity Score (BVAS) and a reduction in proteinuria in the majority of patients; however, a third of patients relapsed 136 . Data on B cell subsets and reconstitution following B cell depletion were not available in this study.
Nephrotic syndromes. B cell depletion strategies have enabled dissection of the functional role of B cells in the pathogenesis of various nephrotic states. In membranous glomerulonephritis, rituximab therapy is effective in two-thirds of patients and is presumed to act through a reduction in the levels of pathogenic anti-phospholipase A2 receptor (PLA2R) or anti-thrombospondin type 1 domain-containing protein 7A (THSD7A) antibodies 143 . Significant increases in T reg cells in responders following rituximab therapy have also been noted 144 . Rituximab seems to have similar efficacy to cyclophosphamide in inducing complete remissions (less so for partial remissions) and has a better safety profile 145 .
In relapsing or steroid-dependent minimal change disease, anecdotal reports exist of success with rituximab, and its effects may be in part due to its direct inhibition of the downregulation of acid sphingomyelinase-like phosphodiesterase 3b in podocytes, resulting in stabilization of the actin cytoskeleton and preventing podocyte apoptosis 5 . Moreover, rituximab might have an indirect effect in correcting T reg cell:T H 17 cell and CD4 + T cell:CD8 + T cell ratio imbalances that are found in active disease, in a B cell-dependent manner 6 . A study reported that paediatric patients with frequently relapsing or steroiddependent nephrotic syndrome had lower baseline frequencies of immature and mature B cells than agematched healthy controls 146 . Nevertheless, the researchers found that, similar to the result that was observed in patients with SLE, delayed repopulation by class-switched memory B cells protected against disease relapse, again suggesting a benefit of depleting memory B cells. A pathogenic role of B cells is consistent with data from a B celldependent in vivo mouse model of proteinuria, in which podocyte damage was dependent on B cell-derived IL-4 (ref.
147
). Lymphocytes from paediatric patients with minimal change nephrotic syndrome express high levels of this cytokine when stimulated ex vivo 148 .
Targeting B cells
Specific targeting of B cells, rather than generalized leukocyte ablation using agents such as cyclophosphamide, was introduced for the treatment of B cell lymphomas and leukaemias and was used for the treatment of conditions with an autoantibody component, such as RA 149 . Diverse B cell surface markers and growth factors have been selected to generate monoclonal antibodies that target B cells ( fig. 3 ) and exert various clinical effects.
CD20 is the target of a number of agents, including rituximab, which depletes B cells through complementdependent and complement-independent pathways 150 . Other B cell-directed biologic therapies include epratuzumab, which targets CD22, a lectin that is found on mature and some immature B cells; alemtuzumab, which targets CD52, a glycoprotein that is highly expressed on B cells and T cells, and at lower levels on myeloid cells; and MEDI-551, which targets CD19, a cell surface protein that regulates BCR signalling and is found on all B cells 151, 152 . In addition, crucial B cell growth factors, such as BAFF and A proliferation-inducing ligand (APRIL), have been targeted in their soluble forms using various agents, such as belimumab, tabalumab, blisibimod and atacicept 122 . These growth factor pathways can also be targeted by the use of GSK2857916, which inhibits B cell maturation antigen (BCMA), a receptor for BAFF and APRIL.
B cell-targeting therapies are now being tested in combination; for example, rituximab has been used with belimumab in clinical trials to treat patients with SLE and Sjögren syndrome [153] [154] [155] [156] . The rationale for the use of this combination is that the levels of BAFF increase following depletion of B cells with rituximab, which may contribute to B cell differentiation and activation following repopulation 157 . In patients with primary immune thrombocytopenia, antibody-secreting cells were the major splenic B cell population that was resistant to rituximab. In patients who had not received rituximab, antibody-secreting cells were predominantly short-lived plasmablasts, whereas in treatment-refractory patients they were phenotypically long-lived plasma cells 158 . This finding suggests that following B cell depletion, the ensuing cytokine milieu, which includes increased BAFF levels, may promote the generation of long-lived plasma cells. The combined use of rituximab and belimumab may therefore prevent the establishment of these long-lived plasma cells, although this hypothesis remains to be tested.
B cell depletion and/or modulation therapy is an expanding field -numerous novel B cell-targeting monoclonal antibodies are being generated and new rituximab biosimilars are entering the clinic 159 . Differences in the B cell populations that are targeted by these agents will have an effect on the extent of B cell depletion, the efficacy of the therapy, the production of autoantibodies and the potential for adverse effects 160 . Of note, B cell depletion agents directed at CD20 or CD22 do not target plasma cells and plasmablasts, which lack expression of these cell surface markers. Nevertheless, in patients with RA or AAV, B cell depletion with these treatments is associated with a reduction in autoantibody levels, presumably through reduced maturation of B cells to plasmablasts and short-lived plasma cells, which are important sources of autoantibodies 31 ( fig. 4 ).
Direct targeting of plasma cells with high doses of glucocorticoids and proteasome inhibitors has also been attempted in the treatment of alloimmune and autoimmune diseases. Bortezomib is a proteasome inhibitor that prevents the degradation of misfolded proteins; the resulting accumulation of these proteins leads to cell cycle arrest and apoptosis in secretory cells. The BORTEJECT trial found no clinical benefit of bortezomib treatment in patients with late antibodymediated transplant rejection 161 . In the ongoing TAVAB trial, bortezomib is being used to treat various refractory autoantibody diseases, including SLE, RA and myasthenia gravis 162 . This trial will assess whether bortezomib induces changes in autoantibody levels.
The use of combinations of rituximab and proteasome inhibitors to treat resistant autoimmune diseases has been reported in small case series of various autoantibody-mediated haematological diseases. These combinations demonstrated efficacy in 77% of cases and induced complete remission in 38% of cases 163 . Novel anti-CD38 monoclonal antibodies that specifically target plasma cells are being tested in multiple myeloma 164 and may prove useful for the treatment of antibody-mediated autoimmune diseases. Finally, chimeric antigen receptor (CAR) T cells, which are engineered to target specific antigens, including CD19 or CD22, have emerged as effective B cell depletion therapies in the treatment of B cell haematological malignancies 165 . Similar therapies aimed at antigens that could discriminate between memory and regulatory B cells may offer hope for more targeted B cell therapies in the future.
Adverse effects of B cell depletion B cell depletion agents are increasingly used to treat various diseases. Although generally safe with regards to risk of infection and malignancies, their use is associated with some important adverse events. In addition, particular agents may affect some B cell subpopulations more than others, resulting in different types of immune responses that might affect the range and severity of harmful effects. Non-B cell-depleting agents can also affect B cell subsets, raising the possibility that particular drug combinations could be used to increase the ratio of B reg cells to pro-inflammatory B cells 166 .
Following treatment with a dose of rituximab (with additional tacrolimus and mycophenolate), CD20-expressing B cells are effectively depleted from the circulation in humans, but some CD20 − B cells persist, most of which are memory B cells 167 . By contrast, in the lymph nodes, the total number of B cells is unaltered, but CD20
+ naive B cells and some memory B cell subsets 169 . Epratuzumab inhibits IL-6 and TNF production by B cells in vitro, but IL-10 production is unaffected. This effect on cytokine production contributes to establishing a regulatory cytokine environment, but a specific effect on B reg cells has not been described.
Depletion of B cell subsets can lead to reduced T cell activation and in turn to loss of viral surveillance. Consequently, reactivation of viruses can occur, particularly in the case of hepatitis B infection, in which a significant number of patients can reactivate more than 6 months after their last dose of rituximab 170 . Current guidelines recommend the prophylactic use of antiviral drugs in these patients 170 . A small number of cases of progressive multifocal leukoencephalopathy related to JC virus infection have also been reported in patients treated with rituximab, either alone or following other immunosuppressive therapies 171 . Patients should be counselled about this risk, for which no obvious preventive strategy exists at present.
Hypogammaglobulinaemia following B cell depletion therapy or targeting of B cell growth factors is common, occurring in 30-56% of patients with AAV after rituximab treatment 172, 173 and in up to 2% of patients with SLE in the first year of belimumab therapy, with levels falling by a median of 13% after 4 years of treatment 174 . Total dose exposure of rituximab therapy may not predict hypogammaglobulinaemia, as this antibody deficiency is more likely to be related to the duration of B cell depletion 173 . In the case of belimumab, IgG levels decrease in the first year of therapy but stabilize thereafter 174 . Infection susceptibility is related to the severity of hypogammaglobulinaemia and can be established functionally by assessing responses to vaccination and modulated by the use of intravenous immunoglobulin replacement 173 . The future introduction of rituximab biosimilars and other B cell depletion agents might lead to different adverse effects, which should be carefully assessed. In patients with RA, rituximab infusion reactions occur in ~25% of patients, and anti-drug antibodies (ADAs) are detected in 11% of patients 175 . Immunogenicity is increasingly recognized as a potential impediment to the safety and efficacy of biological therapy, but a rigorous evaluation of the incidence and the clinical consequences of ADAs is still awaited.
Conclusions
B cells have complex functions in immune-mediated diseases, including in many systemic diseases that affect the kidneys, and in the immunological response to kidney transplantation. B cells can enhance immune responses and promote disease via the production of antibodies and cytokines as well as via antigen presentation. However, B cells with regulatory properties can also arise during and function to limit inflammatory responses. Various B reg cell subsets have been described, including IL-10-producing CD24 hi CD38 hi immature B cells and CD24 + CD27
+ memory B cells. B reg cells have been studied in various autoimmune diseases with kidney involvement, in which they are often numerically deficient and/ or functionally aberrant. However, the use of B reg cells as markers of disease activity has proved to be difficult.
Total B cell depletion seems to be a highly efficacious therapy for a number of immune-mediated renal diseases, even though B reg cells are also depleted in the process. Investigations of the mechanisms through which B cell depletion therapy is effective in particular disease states are ongoing. However, current therapies likely act through a combination of reduced antibody secretion and antigen presentation by B cells as well as the expansion and reversal of functional abnormalities of B reg cells following repopulation (fig. 4) . Future prospects for B cell-targeting therapies may involve combinations of treatments to deplete pro-inflammatory subsets and expand regulatory subsets of B cells.
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